Companies › Frantz Viral Therapeutics
1 active drug program in 4 registered trials: 4 Phase 2; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Artesunate vaginal insert Artemisinin derivative with antimalarial and anti-inflammatory properties; mechanism in CI | – | Phase 2 | Vulvar Diseases; Anal High Grade Squamous Intraepithelial Lesion; CIN 2/3; Anal High-grade Squamous Intraepithelial Lesion | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06075264 | Artesunate vaginal insert | Phase 2 | Vulvar Diseases | Infectious disease | Dec 2026 |
| NCT05555862 | Artesunate vaginal insert | Phase 2 | Anal High Grade Squamous Intraepithelial Lesion | Infectious disease | Dec 2026 |
| NCT04098744 | Artesunate vaginal insert | Phase 2 | CIN 2/3 | Infectious disease | Dec 2026 |
| NCT06206564 | Artesunate vaginal insert | Phase 2 | Anal High-grade Squamous Intraepithelial Lesion | Infectious disease | Dec 2026 |
No annotated target.
–
Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Grand Theravac Life Sciences (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.